Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Has a Prostate-specific Antigen (PSA) level ≥2.0 ng/mL at Screening
Has a screening serum testosterone level \>150 ng/dL
Has an Eastern Cooperative Oncology Group (ECOG) score of ≤2
You may not be if
Has had previous or is currently under hormonal management of prostate cancer. However, hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to the Screening Visit
Is currently treated with a 5-alpha reductase inhibitor
Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Is in need of neoadjuvant hormonal therapy
Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Clareo Health | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
